TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of persons with antibody concentrations in the protective range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean pneumococcal antibody concentration after immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DAS28‐4(ESR) remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF‐36 physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Semaglutide exposure (AUC0‐∞ treatment ratios)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma semaglutide concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non‐serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of asymptomatic postoperative deep vein thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Device exchange time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stent insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postprandial elevation of blood triacylglycerol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HA seroprotection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vi seroprotection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Ionized calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in dysmenorrhea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum levels of CRP, TNF‐α, and IL‐10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV testing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in baseline nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate clinical and parasitologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical healing rate of OHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum diuretic and natriuretic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total weekly physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected visual acuity of 20/40 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of relapses
Endpoint domain: Adverse events/effects
Primary endpoint: stent thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: engagement in pleasurable social and physical activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: self-care strategies to cope with illnesses
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mRS score greater than 1 at month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean TDF dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: itching frequency
Endpoint domain: Adverse events/effects
Primary endpoint: restoration of cervical physiological curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intervertebral height restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of CAIV-T in preventing culture-confirmed influenza illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of 5% weight loss goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the NHE program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional outcomes at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Analgesia effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety degree
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour fluctuation of IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary bacterial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: favorable response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dropout rates due to side effects
Endpoint domain: Adverse events/effects
Primary endpoint: RMMA episodes per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total psychopathological scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of infants with 25(OH)D ≥ 20 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ≥ 50% AVM volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone mineral density increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in new vertebral fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Decreased progression of vertebral deformities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Grade B/C POPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Agreement (kappa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gestational weight gain (GWG) within IOM recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of cardiac mortality
Endpoint domain: Mortality/survival
Primary endpoint: major adverse cardiac event (MACE) rate
Endpoint domain: Mortality/survival
Primary endpoint: corneal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: pulmonary function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: cough relief time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reactive hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spectral densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of spontaneous bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: complete spontaneous bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: abdominal pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VAS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Regurgitation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Regurgitation amount (severity score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: performance status score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prothrombin Time (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activated Partial Thromboplastin Time (APTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: D-dimer (DD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete resolution of dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unacceptable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: asthma-related hospitalisations
Endpoint domain: Mortality/survival
Primary endpoint: Mean improvement in NPQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean QALY scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean health care costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Morphine consumption in the first 48 hours after surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CD4/CD8 ratio on postoperative Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Return of C-reactive protein to preoperative values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of T50-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical wear of denture teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M/P ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urinary IL-6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: WOMAC Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC Physical Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximal expiratory flow at 25% remaining vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: nocturnal arousals
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: awake time after sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Intra- and inter-rater reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of health professionals' classifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hopelessness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-rated migraine pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine cannabinoid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: problems due to cannabis use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased LV threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: local failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: incidence of severe late complications
Endpoint domain: Adverse events/effects
Primary endpoint: Injection associated pain during skin penetration phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carryover effect on BGC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of carryover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BGC drop during infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute complete response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed complete response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall complete response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Hamilton Depression Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Explicit and implicit memory detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stimulated C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean individual total cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improved outcomes with full post-PCI bivalirudin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of salivary mutans streptococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: risk of incidental fragility fractures
Endpoint domain: Mortality/survival
Primary endpoint: Thromboembolic Events (TE)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of vertigo symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of balance while standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immediate word recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: delayed recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of time with intragastric pH > 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of time with intragastric pH > 6.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cytokine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma hsCRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal discharge, nasal obstruction, sneezing, nasal itching scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower turbinate colour rating and turbinate congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saccharin transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: viral resuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of persistent elevations in liver aminotransferase levels
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of single‐puncture arthrocentesis technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Monthly average OPD of vision centres
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anti-gp70 V1V2 antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: US-1 primary isolate neutralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralization of tier 2 viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: flow-experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maintenance infusion rates of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: authorization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PSA decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death
Endpoint domain: Adverse events/effects
Primary endpoint: Serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Early discontinuation rates
Endpoint domain: Adverse events/effects
Primary endpoint: muscle rSO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isolation frequency of S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cell density of S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vaginal mucosal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective ratings of aversive effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of acceptable balanced randomization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: meaning in life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of vaginal discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beneficial effect of music on patient recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mild anxiety during surgery
Endpoint domain: Adverse events/effects
Primary endpoint: graft survival rates
Endpoint domain: Mortality/survival
Primary endpoint: acute rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: functioning grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month SUA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: odds of GRM
Endpoint domain: Adverse events/effects
Primary endpoint: Time to adequate visualization of the glottis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mucosal collisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proinflammatory cytokine IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of sVCAM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in mean trough SiDBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Threshold (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow up for retinal screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuity of care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' treatment preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality risk through 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Composite of death, cardiogenic shock, or CHF within the first 2 days
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Active coping with illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correction of local kyphosis angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain resolution
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intentions to exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiovascular stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall improvement in photoaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epidermal thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: increased vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean child 5‐year body mass index (BMI) centiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maternal impaired glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mode of delivery (cesarean section rates)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incremental mean QALYs gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of acute pain management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for topical microbicides
Endpoint domain: Life impact
Endpoint subdomain: null